Comparative study of VM<sub>26</sub>and IFO regimen in advanced stage  non-small-cell lung cancer

doi:10.13406/j.cnki.cyxb.2001.03.039

您当前的位置：

首页 >

文章列表页 >

Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer

更新时间：2024-01-17

- Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer
- Journal of Chongqing Medical University Issue 3, Pages: 335-336(2001)
- 作者机构：
  
  1. 重庆医科大学附属第二临床学院肺科
  2. 重庆医科大学附属第二临床学院肺科,重庆,400010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2001.03.039
  CLC： R734.2
- Published：2001，
扫描看全文
[1]王导新,蒋幼凡,杜先智,薛亚梅.威猛和异环磷酰胺两种方案治疗晚期非小细胞肺癌的对比研究[J].重庆医科大学学报,2001(03):335-336.

Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer. [J]. Journal of Chongqing Medical University (3):335-336(2001)
[1]王导新,蒋幼凡,杜先智,薛亚梅.威猛和异环磷酰胺两种方案治疗晚期非小细胞肺癌的对比研究[J].重庆医科大学学报,2001(03):335-336. DOI： 10.13406/j.cnki.cyxb.2001.03.039.

Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer. [J]. Journal of Chongqing Medical University (3):335-336(2001) DOI： 10.13406/j.cnki.cyxb.2001.03.039.

摘要

目的：为了研究威猛＋表阿霉素＋卡铂方案与异环磷酰胺＋表阿霉素＋顺铂方案分别治疗两组晚期非小细胞肺癌（ＮＳＣＬＣ）的临床疗效和毒副反应。方法：５８例晚期非小细胞肺癌（ＮＳＣＬＣ）作为研究对象，随机分为两组，威猛联合方案组２７例，异环磷酰胺联合方案组３１例。均有病理学依据。每４周为一周期，两个周期后方可评价疗效。结果：威猛联合方案组有效率为３７．０％（１０／２７），中位生存期为８．３个月；异环磷酰胺联合方案组有效率为３８．７％（１２／３１），中位生存期为８．１个月。　两指标均无统计学差异（Ｐ＞０．０５）。毒性反应主要是骨髓抑制，脱发及恶心，呕吐。结论：两种方案临床疗效接近，毒性反应相似，耐受性较好。

Abstract

Objective: To compare the effectiveness and toxicity in treatment of non-small-cell lung cancer with VM26+EPI+CBP regimen and IFO +EPI+DDD regimen.Methods： 58 patients with advanced stage NSCLC were randomizer into VM26group and IFO group.27 patients were treated wit h VM26regimen

31 patients were treated with IFO regimen.Results： The response rate were 37.0%(10/27)for VM26regimen and 38.7%(12/3 1)for IFO regimen

median survival time was 8.3 months for VM26regimen and 8.1 months for IFO regimen.There was no significant difference(P＞0.05) for bothof between two groups. Conclusion：Similar response rate was se en in both groups.The toxicity of myelosuppression of IFO group was a little bit more serious than the toxicity of VM26groups.

关键词

肺癌联合化疗

Keywords

Non-small-cell lung cancerCombined chemotherapy

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical study of paclitaxel combined with cisplatin in treatment of pulmonary metastasis tumor

FAT regiment for patients with relapsed,refractory acute leukemia

Related Author

ZHANG Ju

任涛

陈晓品

LUO Yun

et al

陈姝

陈林

周慷

Related Institution

Department of Oncology,the First Affiliated Hospital,Chongqing Medical University

重庆医科大学附属第一医院肿瘤科

Department of Hematology,the Second Affiliated Hospital,Chongqing Medical University

⁰

Comparative study of VM26and IFO regimen in advanced stage non-small-cell lung cancer

DOI：10.13406/j.cnki.cyxb.2001.03.039

摘要

Abstract

关键词

Keywords

references

Comparative study of VM₂₆and IFO regimen in advanced stage non-small-cell lung cancer